BioCentury | Jun 11, 2020

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

Lilly partners with Evox on exosome therapies  Eli Lilly and Co. (NYSE:LLY) entered a collaboration and five-target licensing deal with Oxford-based Evox Therapeutics Ltd. to develop and deliver RNAi and antisense oligonucleotides for neurological disorders...
BC Innovations | Apr 10, 2018
Distillery Therapeutics


INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting IL-6 could help treat glioblastoma. In patients, endothelial cell levels of IL-6 were higher in tumors than in normal brain tissue. In a mouse model...
BC Week In Review | May 16, 2016
Company News

Alder, Vitaeris deal

Alder granted newco Vitaeris exclusive, worldwide rights to clazakizumab, an anti-IL-6 mAb. Alder helped co-found Vitaeris to develop clazakizumab, which the newco plans to develop for chronic inflammatory diseases. Alder received an equity stake in...
BC Extra | May 7, 2016
Company News

Newco Vitaeris licenses Alder's clazakizumab

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) granted newco Vitaeris Inc. (Vancouver, B.C.) exclusive, worldwide rights to anti-IL-6 mAb clazakizumab (formerly ALD518 ). Alder helped co-found Vitaeris to house clazakizumab, which the newco intends to develop for chronic...
BC Week In Review | May 18, 2015
Clinical News

Clazakizumab: Phase IIb data

A double-blind, international Phase IIb trial in 140 patients with moderate to severe RA who had an inadequate response to tumor necrosis factor (TNF) inhibitors showed that both 5 and 25 mg subcutaneous clazakizumab plus...
BC Extra | May 9, 2015
Company News

Alder fleshes out timeline for migraine candidate

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) gained $7.04 (23%) to $37.23 on Friday after spelling out milestones expected next half for migraine candidate ALD403 during its 1Q15 earnings call. Alder plans to begin a pivotal trial in...
BC Extra | Jan 9, 2015
Financial News

Funding roundup: Alder, Avalanche, OvaScience, Stemline

Four biotechs -- Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Avalanche Biotechnologies Inc. (NASDAQ:AAVL), OvaScience Inc. (NASDAQ:OVAS) and Stemline Therapeutics Inc. (NASDAQ:STML) -- raised a total of $470.5 million in follow-on offerings on Thursday. Migraine and autoimmune therapy...
BC Week In Review | Jan 5, 2015
Clinical News

Clazakizumab: Phase IIb data

A double-blind, dose-ranging Phase IIb trial in adults with active psoriatic arthritis showed that clazakizumab met the primary endpoint of improving ACR20 response rate at week 16 vs. placebo. Specifically, ACR20 response rates at week...
BioCentury | Jan 5, 2015

Guest Commentary: The Tipping Point

That boom you heard on Dec. 22 followed by the thud of Gilead Sciences Inc. 's stock price was the opening shot and initial casualty of a major price war. It had been long in...
BC Extra | Dec 24, 2014
Financial News

Alder proposes $115M follow-on

After completing a downsized IPO in May, Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) is proposing to raise $115 million in a follow-on underwritten by Credit Suisse; Leerink; Wells Fargo; and Sanford Bernstein. The antibody company raised $80...
Items per page:
1 - 10 of 36